Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment reporting

Analytics

Phase 2

4(66.7%)

Phase 3

1(16.7%)

Phase 2/3

1(16.7%)

6Total

Phase 2(4)

Phase 3(1)

Phase 2/3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05665348Phase 2/3Completed

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Role: lead

NCT05706779Phase 2Recruiting

Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

Role: lead

NCT06207981Phase 3Recruiting

Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA

Role: lead

SYF6230cedfee4c42ca985e729371715c1fPhase 2Unknown

PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carcinoma. A non-comparative randomized phase II study

Role: lead

SYF9e63bc7995084e4191f22afacb9a93a2Phase 2Unknown

PRODIGE 55-SOCRATE : A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer

Role: lead

SYFc0d4c3d608c745b2a6a202342926bc48Phase 2Unknown

PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.

Role: lead

All 6 trials loaded